VCIM
ZVRA icon

Velan Capital Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Velan Capital Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-715,000
Closed -$6.3M – 60
2025
Q2 		$6.3M Buy
715,000
+50,000
+8% +$406K 6.22% 5
2025
Q1 		$4.98M Buy
665,000
+365,000
+122% +$2.9M 5.12% 9
2024
Q4 		$2.5M Buy
300,000
+100,000
+50% +$854K 2.16% 9
2024
Q3 		$1.39M Buy
+200,000
New +$1.36M 1.3% 13

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Velan Capital Investment Management's ZVRA Position: Q3 2025 in Review

Velan Capital Investment Management sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 715,000 shares — an estimated $6.3M sold.

Velan Capital Investment Management first reported a position in ZVRA in Q3 2024 and held it in 4 quarters. The position peaked at $6.3M in Q2 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

  • Velan Capital Investment Management reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Velan Capital Investment Management sold 715,000 Zevra Therapeutics shares in Q3 2025, an estimated $6.3M.
  • Velan Capital Investment Management first reported a position in Zevra Therapeutics in Q3 2024 and held it in 4 quarters.
  • Velan Capital Investment Management's Zevra Therapeutics position peaked at $6.3M in Q2 2025.
  • 166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Velan Capital Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.